Intellia Therapeutics (NTLA) Trading Up 5.1%

Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) were up 5.1% during mid-day trading on Wednesday . The company traded as high as $20.38 and last traded at $19.39. Approximately 1,321,530 shares changed hands during trading, an increase of 48% from the average daily volume of 894,712 shares. The stock had previously closed at $18.45.

A number of analysts have recently issued reports on NTLA shares. Raymond James started coverage on shares of Intellia Therapeutics in a report on Thursday, September 20th. They set a “market perform” rating for the company. BidaskClub raised shares of Intellia Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, September 15th. ValuEngine downgraded shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, September 22nd. Zacks Investment Research downgraded shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 7th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $57.50 price objective on shares of Intellia Therapeutics in a report on Friday, August 24th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $35.50.

The firm has a market capitalization of $801.09 million, a PE ratio of -10.31 and a beta of 3.87.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Wednesday, October 31st. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.05). Intellia Therapeutics had a negative return on equity of 31.70% and a negative net margin of 308.81%. The company had revenue of $7.41 million for the quarter, compared to the consensus estimate of $11.58 million. During the same period in the prior year, the firm posted ($0.44) earnings per share. The business’s revenue was up 1.2% on a year-over-year basis. On average, research analysts predict that Intellia Therapeutics Inc will post -2.05 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Macquarie Group Ltd. bought a new stake in Intellia Therapeutics in the second quarter worth $101,000. Patriot Financial Group Insurance Agency LLC bought a new stake in Intellia Therapeutics in the third quarter worth $116,000. Nikko Asset Management Americas Inc. bought a new stake in Intellia Therapeutics in the third quarter worth $141,000. Legal & General Group Plc lifted its stake in Intellia Therapeutics by 75.4% in the second quarter. Legal & General Group Plc now owns 5,427 shares of the company’s stock worth $149,000 after purchasing an additional 2,333 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Intellia Therapeutics by 519.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,733 shares of the company’s stock worth $157,000 after purchasing an additional 4,807 shares during the last quarter. 66.59% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Intellia Therapeutics (NTLA) Trading Up 5.1%” was reported by WKRB News and is owned by of WKRB News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.wkrb13.com/2018/11/08/intellia-therapeutics-ntla-trading-up-5-1.html.

About Intellia Therapeutics (NASDAQ:NTLA)

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Recommended Story: Technical Analysis

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply